The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 FDA Approval Unlikely Due to Patent Economics Stefano M. Sinicropi, MD posted on the topic LinkedIn Why Are People Injecting Themselves with Peptides? The New Yorker When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions